Ivabradine

Ivabradine is a cardiovascular drug classed as a selective sinus-node inhibitor, meaning it lowers heart rate by acting on the heart's own pacemaker rather than on the wider cardiovascular system ^[1]. Chemically it is a benzazepine derivative, and it was known during development by the code S 16257 ^[1]. Its defining feature is that it slows the heart while leaving the strength of each contraction, the conduction of the electrical impulse, and blood pressure essentially unchanged ^[1][4].

The drug was developed by the French company Servier. It was approved in the European Union in 2005 and is sold across much of the world as Procoralan, with further brand names such as Corlentor and Coralan in various countries ^[1]. The United States Food and Drug Administration approved it in 2015 under the name Corlanor, where it has been distributed by Amgen ^[1].

Its established uses are in chronic heart failure with reduced ejection fraction and in chronic stable angina ^[1]. In the large SHIFT trial, adding ivabradine to standard therapy in patients who remained in sinus rhythm with an elevated resting heart rate lowered the combined risk of cardiovascular death and hospital admission for worsening heart failure, an effect driven mainly by fewer heart-failure hospitalizations ^[2]. For angina it reduced the frequency of attacks and improved exercise tolerance to a degree comparable with the beta-blocker atenolol ^[4]. The BEAUTIFUL trial in stable coronary disease with left-ventricular dysfunction did not improve the main outcome overall, although a benefit appeared in a subgroup with higher baseline heart rates ^[3]. Beyond these approved settings, it has been used off-label for inappropriate sinus tachycardia and studied in postural orthostatic tachycardia syndrome ^[1].

Ivabradine is a prescription medicine taken by mouth, usually as tablets given twice daily ^[1][2]. It is intended for people in normal sinus rhythm, because its rate-slowing action depends on the sinus node driving the heartbeat ^[1].

The most characteristic side effect is the appearance of brief luminous visual phenomena called phosphenes, which arise from the drug's action on related channels in the retina and are generally mild and reversible ^[2]. Excessive slowing of the heart, or bradycardia, can occur, and an increased incidence of atrial fibrillation has been reported with its use ^[1][2].

Ivabradine is a prescription medicine. Common effects include brief flashes of brightness known as phosphenes, a slow heart rate and headache, and it can trigger or worsen atrial fibrillation. It is not used in acute decompensated heart failure, severe bradycardia or sick sinus syndrome. Strong inhibitors of the CYP3A4 enzyme, including some heart rate lowering calcium channel blockers and azole antifungals, raise its levels dangerously and should be avoided.

Ivabradine is a highly sensitive substrate of the cytochrome P450 3A4 enzyme (CYP3A4) and undergoes significant pharmacokinetic interactions with CYP3A4 inhibitors ^{[12] [13] [14]}. Strong CYP3A4 inhibitors including ketoconazole, diltiazem, and verapamil increase ivabradine plasma concentrations substantially; co-administration with ketoconazole-like inhibitors can nearly double ivabradine exposure and its metabolite concentrations, elevating the risk of excessive heart rate reduction and bradycardia. This is a pharmacokinetic interaction in which the inhibitor reduces ivabradine clearance. Additionally, grapefruit juice has been documented to increase ivabradine exposure through the same CYP3A4 mechanism.

Clinical trial data revealed that ivabradine combined with diltiazem or verapamil (both heart rate-lowering calcium channel blockers) led to adverse outcomes including increased atrial fibrillation and acute coronary events in some patient subgroups ^{[15] [16]}, suggesting both pharmacokinetic and pharmacodynamic additive effects. Combinations with beta-blockers, ACE inhibitors, and most other cardiovascular drugs have not been systematically studied for this specific pharmacokinetic interaction.

Checking a whole stack? Run it through interactions + stacks.

Ivabradine was developed by the French pharmaceutical company Servier as a purpose-built inhibitor of the sinoatrial node's pacemaker current, the so-called funny current (If). Its design reflected a deliberate strategy to lower heart rate through a single, well-defined ionic mechanism, without the effects on contractility, conduction, or blood pressure that accompany beta-blockers and calcium-channel blockers. The drug reached European markets in 2005 under the names Procoralan and Corlanor, initially for chronic stable angina.

Its standing was substantially strengthened by the landmark SHIFT trial, published in 2010, which enrolled more than six thousand patients and showed that ivabradine reduced cardiovascular death and heart-failure hospitalization in chronic systolic heart failure with elevated resting heart rate. The United States Food and Drug Administration approved it in 2015 for heart failure. The BEAUTIFUL and SIGNIFY trials, by contrast, found no overall benefit in stable coronary disease without heart failure, helping to define the population in which the drug is most useful.

Ivabradine occupies a distinctive and respected niche in cardiology as the first agent able to slow the heart through pure inhibition of the sinus-node pacemaker current. Clinicians value it precisely because it lowers heart rate without depressing the force of contraction or dropping blood pressure, which makes it useful in patients who cannot tolerate the doses of beta-blockers that would otherwise be needed. Its benefit in chronic systolic heart failure with elevated heart rate is grounded in a large, well-conducted outcomes trial, lending it a solid evidence base.

It has also attracted interest for inappropriate sinus tachycardia and postural tachycardia syndrome, where its mechanism is particularly apt. The honest limits are clear: it works only in patients in sinus rhythm, offers no advantage in stable coronary disease without heart failure, and commonly produces transient luminous visual sensations called phosphenes. Within its proper population, it is a genuinely elegant and effective tool.